Personalized peptide vaccine for treatment of advanced cancer
Tetsuro Sasada, Akira Yamada, Masanori Noguchi
1Department of Immunology and Immunotherapy, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan. tsasada@med.kurume-u.ac.jp.
Abstract:
The field of cancer immunotherapy has moved forward drastically in the past 20 years, since many tumor-associated antigens (TAA) have been identified. Although various approaches for therapeutic cancer immunotherapies, including peptide-based vaccines, have been developed and clinically examined, the complexity and diversity of tumor cell characteristics and host immune cell repertoires seem to limit the therapeutic efficacy of this treatment modality. Considering the diversity of immune responses against heterogeneous tumor cells, tailored selections of vaccine antigens appropriate for individual patients could be a rational approach for developing effective cancer vaccines. We have developed a novel immunotherapeutic approach called personalized peptide vaccine (PPV), in which a maximum of four human leukocyte antigen (HLA)-matched vaccine peptides were selected based on the pre-existing host immunity before vaccination. We conducted a series of phase I and phase II clinical trials of PPV, which have shown better antigen-specific immune responses and promising clinical outcomes in patients with various types of advanced cancers. Further randomized phase III trials would be recommended to prove the clinical benefits of PPV. In addition, novel biomarkers for selecting patients who would benefit most from PPV remain to be identified.
Insights
Personalized peptide vaccines (PPV) tailor antigen selection based on individual immune responses. Clinical trials show PPV enhances immune responses and offers promising outcomes for advanced cancer patients.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Cancer immunotherapy has advanced significantly due to tumor-associated antigen (TAA) identification.
- Current immunotherapies, including peptide vaccines, face limitations due to tumor and immune system complexity.
- Individualized antigen selection is crucial for effective cancer vaccine development.
Purpose of the Study:
- To introduce and evaluate a novel personalized peptide vaccine (PPV) approach.
- To assess the safety and efficacy of PPV in patients with advanced cancers.
- To explore the potential of PPV in improving therapeutic outcomes.
Main Methods:
- Developed a personalized peptide vaccine (PPV) strategy.
- Selected up to four HLA-matched vaccine peptides based on pre-existing host immunity.
- Conducted phase I and phase II clinical trials of PPV in cancer patients.
Main Results:
- PPV demonstrated enhanced antigen-specific immune responses.
- Promising clinical outcomes were observed in patients with various advanced cancers.
- The approach showed feasibility and potential for personalized cancer treatment.
Conclusions:
- Personalized peptide vaccines (PPV) represent a rational and effective approach for cancer immunotherapy.
- Further randomized phase III trials are recommended to confirm clinical benefits.
- Identification of biomarkers for patient selection is essential for optimizing PPV efficacy.
More Related Videos
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers